“Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.”, Hum Vaccin Immunother, vol. 8, no. 5, pp. 630-8, 2012.
, “A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.”, AIDS Res Hum Retroviruses, vol. 26, no. 8, pp. 933-42, 2010.
, ,